MAP2K1 and early-onset autosomal dominant Alzheimer disease: “Trametinib, a MEK1/2 inhibitor, promotes adult neurogenesis in an Alzheimer’s disease mouse model and human iPSC-derived neural stem cells." Researchers have discovered that trametinib, a MEK1/2 inhibitor, can enhance adult neurogenesis and replenish neurons in brain areas where neurodegeneration most affects Alzheimer’s disease (AD).